natgillin/translations-raw huggingface dataset:
a Data er kumulative fra AURA-forlængelsesstudiet (fase II) og AURA2-studiet; kun bivirkninger hos patienter, der fik mindst én dosis Tagrisso, er medtaget. b National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. c Inkluderer tilfælde inden for termgruppen: Interstitiel lungesygdom og pneumonitis. d Der blev indberettet 4 tilfælde af CTCAE-grad 5 (dødelige). e Inkluderer tilfælde inden for termgruppen udslæt: Udslæt, generelt udslæt, erytematøst udslæt, makuløst udslæt, makulopapuløst udslæt, papuløst udslæt, pustuløst udslæt, erytem, folliculitis, akne, dermatitis og acneiform dermatitis. f Inkluderer tilfælde inden for termgruppen: Tør hud, hudfissurer, xerose, eksem. g Inkluderer tilfælde inden for termgruppen: Neglelejesygdom, neglelejeinflammation, neglelejeømhed, neglemisfarvning, neglesygdom, negledystrofi, negleinfektion, negleriller, onykoklase, onykolyse, onykomadose, paronychion. h Repræsenterer incidensen af laboratoriefund, ikke af rapporterede bivirkninger.
a Data is cumulative from AURA extension (Phase II) and AURA 2 studies; only events for patients receiving at least one dose of TAGRISSO are summarized. b National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. c Includes cases reported within the clustered terms: Interstitial lung disease and pneumonitis. d 4 CTCAE grade 5 events (fatal) were reported. e Includes cases reported within the clustered terms for rash AEs: Rash, rash generalised, rash erythematous, rash macular, rash maculo-papular, rash papular, rash pustular, erythema, folliculitis, acne, dermatitis and dermatitis acneiform. f Includes cases reported within the clustered terms: Dry skin, skin fissures, xerosis, eczema. g Includes cases reported within the clustered terms: Nail bed disorder, nail bed inflammation, nail bed tenderness, nail discoloration, nail disorder, nail dystrophy, nail infection, nail ridging, onychoclasis, onycholysis, onychomadesis, paronychia. h Represents the incidence of laboratory findings, not of reported adverse events.
a Den første dosis gives i 2-måneders-alderen.
a The first dose should be given at 2 months of age.
a Den samlede dosis pr. cyklus var 100 mg/m2
a The total dose per cycle was 100 mg/m2
a Der er ikke medtaget patientbesøg fra datoen for den første transfusion, behandling med erytropoietin eller behandling med vækstfaktorer.
a Excludes pateints visits from date of first transfusion, treatment with erythropoietin, or treatment with growth factors.
a Der er ikke medtaget patientbesøg fra datoen for den første transfusion, behandling med erytropoietin eller behandling med vækstfaktorer.
a Excludes patients visits from date of first transfusion, treatment with erythropoietin, or treatment with growth factors.
a Der er rapporteret dødelige tilfælde i afsluttede eller igangværende kliniske studier. b Der er rapporteret livstruende tilfælde i afsluttede eller igangværende kliniske studier. c Hyppigheden af bivirkninger i systemorganklassen hjerte var, uanset kausalitet, højere i nivolumabgruppen end i kemoterapigruppen i post-CTLA4/BRAF-hæmmer-populationen af patienter med metastatisk melanom.
a Fatal cases have been reported in completed or ongoing clinical studies b Life-threatening cases have been reported in completed or ongoing clinical studies. c The frequency of adverse events in the cardiac disorders system organ class regardless of causality was higher in the nivolumab group than in the chemotherapy group in post-CTLA4/BRAF inhibitor metastatic melanoma population.
a Der er yderligere information under “Beskrivelse af udvalgte bivirkninger”. b MedDRA’s high level group terms (MedDRA version 16.1).
a Additional information is provided in “Description of selected adverse reactions”. b MedDRA high level group terms (MedDRA version 16.1).
a Disse bivirkninger blev identificeret under post-marketing-overvågning, men hyppigheden er dog estimeret ud fra en statistisk beregning baseret på det totale antal patienter, der har været eksponeret for atazanavir (med og uden ritonavir) i randomiserede, kontrollerede og andre tilgængelige kliniske studier (n = 2.321). b Se afsnittet Beskrivelse af udvalgte bivirkninger for flere oplysninger.
a These adverse reactions were identified through post-marketing surveillance; however, the frequencies were estimated from a statistical calculation based on the total number of patients exposed to atazanavir (with and without ritonavir) in randomised controlled and other available clinical trials (n = 2321). b See section Description of selected adverse reactions for more details.
a Disse bivirkninger blev identificeret under post-marketing-overvågning, men hyppigheden er dog estimeret ud fra en statistisk beregning baseret på det totale antal patienter, der har været eksponeret for REYATAZ i randomiserede, kontrollerede og andre tilgængelige kliniske studier (n = 2.321). b Se Beskrivelse af udvalgte bivirkninger.
a These adverse reactions were identified through post-marketing surveillance, however, the frequencies were estimated from a statistical calculation based on the total number of patients exposed to REYATAZ in randomised controlled and other available clinical trials (n = 2321). b See description of selected adverse reactions for more details.
a Disse kriterier opfylder National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998) definition på ≥ CTC grad 2 blødning.
These criteria meet the National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998) definition of ≥CTC Grade 2 bleeding
a Disse kriterier opfylder National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998) definition på ≥CTC grad 2 blødning.
a These criteria meet the National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998) definition of ≥ CTC Grade 2 bleeding
a Disse kriterier opfylder National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998) definition på ≥CTC grad 2 blødning.
a These criteria meet the National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998) definition of ≥CTC Grade 2 bleeding
a Disse kriterier opfylder National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998) definition på ≥CTC grad 2 blødning.
a These criteria meet the National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998) definition of ≥CTC Grade 2 bleeding.
A Efter påbegyndelse af behandlingen med 5 månedlige injektioner
A After treatment initiation with 5 monthly injections
a En person kan være repræsenteret i flere rækker. b Hændelsesraten (%/år) er beregnet som antal hændelser/personårs-eksponering. c Den tosidede p-værdi er baseret på non-inferioritetsmarginen på 1,38.
a A subject can be represented in multiple rows. b The event rate (%/yr) is calculated as number of events/subject-year exposure. c The two-sided p-value is based on the non-inferiority margin of 1.38.
a En-sidet p-værdi fra en stratificeret log-rank-test.
a One-sided p-value from a stratified log-rank test
A Endepunkter med bekræftet superioritet for Xultophy versus komparator
A Endpoints with confirmed superiority of Xultophy vs comparator
A Enten 9 mg/ml (0,9%) natriumchloridinfusionsvæske eller 50 mg/ml (5%) glucoseinfusionsvæske.
A Either 9 mg/mL (0.9%) sodium chloride for infusion or 50 mg/mL (5%) glucose for infusion.
a ere
nger nger
a ESRD= End-Stage Renal Disease opretholdt med hæmodialyse b Baseline middel kreatininclearance beregnet efter Cockcroft-Gaults ligning
a ESRD= End-stage renal disease maintained on haemodialysis b Baseline mean creatinine clearance as calculated by Cockcroft-Gault equation
a Et succesfuldt globalt respons blev defineret som både klinisk og mikrobiologisk succes. b EOIVT (End of Intravenous Treatment), afslutning af intravenøs behandling; EOT (End of All Treatment), afslutning af al behandling.
a A successful global response was defined as both clinical and microbiologic success b EOIVT, End of Intravenous Treatment; EOT, End of All Treatment
a f.eks. blødning fra blærecancer, mavecancer, tarmcancer
a e.g. bleeding from bladder cancer, gastric cancer, colon cancer
a Faslodex er indiceret til patienter med recidiverende eller progredierende sygdom under antiøstrogen-behandling.
a Faslodex is indicated in patients whose disease had recurred or progressed on an anti-estrogen therapy.
a Feltstyrker fra faste sendere, såsom stationer til mobil- og trådløse telefoner, mobilradioer, amatørradioer, AM- og FM-radioudsendelser og tv-udsendelser kan ikke forudsiges teoretisk med nøjagtighed.
Field strengths from fixed transmitters, such as base stations for radio (cellular/cordless) telephones and land mobile radios, amateur radio, AM and FM radio broadcast and TV broadcast cannot be predicted theoretically with accuracy.
a FEV1 = forceret eksspiratorisk volumen i det første sekund b NA = ikke tilgængeligt c GINA-klassifikationen er baseret på Global Initiative for Asthma (GINA)-definitionen: GINA trin 4-patienter fik medium- til højdosis-ICS plus et andet forebyggende middel.
a FEV1=forced expiratory volume in 1 second b NA=not available c The GINA classification is based on the Global Initiative for Asthma (GINA) definition: GINA step 4 patients received medium- to high-dose ICS plus another controller.
A Fjern folieforseglingen fra en ny nål.
Remove the protective seal from a new needle.
a For at beregne injektionsvolumen (ml) for patienter < 60 kg skal følgende formel anvendes: kropsvægt (kg) x 0,0083 (ml/kg); se også tabel 2.
a To calculate the volume of injection (mL) for patients < 60 kg, use the following formula: body weight (kg) x 0.0083 (mL/kg) or see Table 2.
a Foretrukket term i MedDRA (version 15.0) b Der var ingen bivirkninger af grad 5 for Cyramza.
a MedDRA preferred term (Version 15.0) b There were no Grade 5 ADRs for Cyramza.
a Forskellen i andele og dets 95 % CI’er mellem randomiserede behandlingsgrupper er baseret på normal approksimation.
a The difference in proportions and its 95% CIs between randomised treatment groups is based on normal approximation.
a Forsøg I efter 24 uger, Forsøg II efter 26 uger og Forsøg III efter 24 og 52 uger b 40 mg Trudexa givet hver anden uge c MTX = methotrexat
a Study I at 24 weeks, Study II at 26 weeks , and Study III at 24 and 52 weeks b 40 mg Trudexa administered every other week c MTX = methotrexate
a Fra en 2-sidet log-rank test.
a From a 2-sided log-rank test.
a Frekvens er baseret på bivirkningsdata.
a Frequency is based on adverse event data.
A FREMSTILLER ANSVARLIG FOR BATCHFRIGIVELSE
MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE
A FREMSTILLER ANSVARLIG FOR BATCHFRIGIVELSE‌
MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
a Fuldstændigt analysedatasæt (FAS)
a Full analysis set (FAS)
a Fuldstændigt analysedatasæt (FAS) - Gennemføreres ved brug af sidste observation føres videre (LOCF) forud for akut blodsukkerregulerende behandling
a Full analysis set (FAS) - Completers using last observation carried forward (LOCF) prior to glycaemic rescue therapy
a Fuldstændigt analysedatasæt (FAS) ved brug af sidste observation føres videre (LOCF) forud for akut blodsukkerregulerende behandling
a Full analysis set (FAS) using last observation carried forward (LOCF) prior to glycaemic rescue therapy
a Fuldstændigt analysedatasæt (FAS) ved brug af sidste observation føres videre (LOCF) forud for akut blodsukkerregulerende behandling b Op til 4 mg glimepirid
a Full analysis set (FAS) using last observation carried forward (LOCF) prior to glycaemic rescue therapy b Up to 4 mg glimepiride
a Fuldstændigt analysedatasæt (FAS) ved brug af sidste observation føres videre (LOCF) forud for akut blodsukkerregulerende behandling,
a Full analysis set (FAS) using last observation carried forward (LOCF) prior to glycaemic rescue therapy
a Fuldstændigt analysedatasæt (FAS) ved brug af sidste observation føres videre (LOCF) før blodsukkerregulerende behovsbehandling. b Op til 4 mg glimepirid.
a Full analysis set (FAS) using last observation carried forward (LOCF) prior to glycaemic rescue therapy b Up to 4 mg glimepiride
a Fuldstændigt analysedatasæt (FAS) ved brug af sidste observation føres videre (LOCF) før blodsukkerregulerende behovsbehandling. bUndergruppeanalyse af patienter, der også fik metformin (FAS, LOCF).
a Full analysis set (FAS) using last observation carried forward (LOCF) prior to glycaemic rescue therapy bSubgroup analysis for patients on additional background of metformin (FAS, LOCF)
a Fuldstændigt analysedatasæt (FAS).
a Full analysis set (FAS)
a Fuldt analysesæt omfattede alle randomiserede patienter (”intent-to-treat”-population). b Ved brug af negativ histologi alene til at definere komplet respons iblandt patienter, der havde mindst partielt respons fra andre modaliteter (MRI eller fotografi), resulterede i en komplet respons-rate på 22,7 %.
a Full analysis set included all randomised patients (intent-to-treat population). b Using only negative histology to define CR among patients who have at least a PR from other modalities (MRI or photography) resulted in a CR rate of 22.7%.
a Følgende bivirkninger er ikke anført, men medregnes også i hyppigheden for lokale reaktioner: varmefølelse, paræstesi på infusionsstedet. b Gravitationelt ødem/genital hævelse er observeret efter administration i de nedre abdominale kvadranter.
a The following ADRs are not listed but also calculated in the frequency for Local reactions: feeling hot, infusion site paresthesia. b Gravitational oedema/genital swelling was observed subsequent to lower abdominal quadrants administration.
a Følsomhedsscores for genotype beregnes ved at lægge følsomhedsværdier for lægemidler sammen (1 = følsom; 0 = nedsat følsomhed) for alle lægemidler i baggrundsregimet ved baseline.
a Genotypic sensitivity scores are calculated by summing up drug susceptibility values (1 = sensitive; 0 = reduced susceptibility) on all drugs in the baseline background regimen.
a Gennemsnittet af tre tællinger i 2 sekunder eller én tælling i 10 sekunder
a Average of three 2-second counts or one 10-second count
a Hensigt-til-at-behandle kohorte
a Intent-to-treat cohort.
a Herpes zoster er en sammensat term, der omfatter følgende termer: herpes zoster, oral herpes og herpes virusinfektion. b Pneumoni er en sammensat term, der omfatter følgende termer: pneumoni, atypisk pneumoni, bronkopneumoni, lobær pneumoni, bakteriel pneumoni, fungal pneumoni, influenzapneumoni og pneumokokpneumoni. c Termen lymfopeni omfatter følgende termer: lymfopeni og nedsat lymfocyttal. d Termen hoste omfatter følgende termer: hoste, produktiv hoste og øvre luftvej-hoste-syndrom.
a The term herpes zoster is a grouping of the following terms: herpes zoster, oral herpes, and herpes virus infection. b The term pneumonia is a grouping of the following terms: pneumonia, atypical pneumonia, bronchopneumonia, lobar pneumonia, bacterial pneumonia, fungal pneumonia, pneumonia influenza, and pneumococcal pneumonia. c The term lymphopenia includes the following terms: lymphopenia and lymphocyte count decreased. d The term cough includes the following terms: cough, productive cough, and upper airway cough syndrome.
a Hjertefrekvens under 60 slag pr. minut (bpm) b Seponér permanent i tilfælde af recidiv.
a Heart rate less than 60 beats per minutes (bpm) b Permanently discontinue in the event of recurrence.
a Hypertrofi af endometriet er en MedDRA-term, som betegner endometriets tykkelse påvist med ultralyd. b Der blev rapporteret overfølsomhedsreaktioner, herunder de bivirkninger, som er angivet under hud og subkutane væv, hævet tunge, faryngalt ødem, følelse af at halsen snører sig sammen.
a Endometrial hypertrophy is a MedDRA dictionary term that represents sonographic endometrial thickness findings. b Hypersensitivity reactions including adverse reactions listed under skin and subcutaneous tissue disorders, swollen tongue, pharyngeal oedema and throat tightening were reported.
a Hyppigheden af vertebrale frakturer blev vurderet hos 448 placebo- og 444 Forsteopatienter, der havde fået taget røntgen- billede af rygsøjlen ved baseline og som opfølgning.
a The incidence of vertebral fractures was assessed in 448 placebo and 444 Forsteo patients who had baseline and follow-up spine radiographs.
a Hændelsesraten (%/år) er beregnet som antal hændelser/personårs-eksponering. b ICH omfatter primær hjerneblødning, subaraknoid blødning, epi-/subdural blødning og iskæmisk apopleksianfald med svær blødningskonversion.
a The event rate (%/yr) is calculated as number of events/subject-year exposure. b ICH includes primary haemorrhagic stroke, subarachnoid haemorrhage, epi
a I behandlingsperioden: Tid fra første dosis af studielægemiddel til den sidste dosis plus 3 dage. b Primært endepunkt for sikkerhed: Klinisk relevante blødninger (sammensætning af svære og klinisk relevante ikke svære blødninger).
a On-Treatment Period: Time from first dose of study drug to last dose plus 3 days. b Primary Safety Endpoint: Clinically relevant bleeding (composite of major and clinically relevant non-major bleeding).
A I de kliniske studier var ribavirin-dosis vægtbaseret (< 66 kg = 800 mg/dag; 66-80 kg = 1.000 mg/dag; 81-105 kg = 1.200 mg/dag; > 105 kg = 1.400 mg/dag), og dosis blev fordelt på to doser sammen med mad.
A In the clinical studies, the dose of ribavirin was weight-based (< 66 kg = 800 mg/day, 66 to 80 kg = 1,000 mg/day, 81 to 105 kg = 1,200 mg/day, > 105 kg = 1,400 mg/day) administered in two divided doses with food.
a I studie 1 blev ændringen fra baseline i den samlede myomvolumen målt med MR-scanning.
a In Study 1, change from baseline in total myoma volume was measured by MRI.
a IMP24011: p-værdier, der sammenligner efalizumab med placebo ved hjælp af logistisk regression, hvor baseline PASI score, tidligere behandling af psoriasis og geografisk område indgik som kovariater.
IMP24011: p-values compared efalizumab with placebo using logistic regression including baseline PASI score, prior treatment for psoriasis and geographical region as covariates.
a Indlæggelse/behandling på skadestue eller behandling med orale steroider b Reduktion i hyppigheden af eksacerbationer er statistisk signifikant (p < 0,01) for begge sammenligninger
a Hospitalisation/emergency room treatment or treatment with oral steroids b Reduction in exacerbation rate is statistically significant (P value <0.01) for both comparisons
a Infusionstiden er 10 minutter og forbliver den samme under hele behandlingen
a Infusion time is 10 minutes and remains consistent throughout the regimen
a Infusionstiden er 30 minutter og forbliver den samme under hele behandlingen
a Infusion time is 30 minutes and remains consistent throughout the regimen
a Inkluderer grad 5-hændelser b Fra spontane rapporter c Inkluderer foretrukne termer for perifer neuropati, perifer motorisk neuropati, polyneuropati, paræstesi, perifer sensorisk neuropati, perifer sensomotorisk neuropati og demyeliniserende polyneuropati d Ingen grad 4-hændelser
a Includes Grade 5 events. b From spontaneous reporting c Includes preferred terms of peripheral neuropathy, peripheral motor neuropathy, polyneuropathy, paraesthesia, peripheral sensory neuropathy, peripheral sensorimotor neuropathy and demyelinating polyneuropathy d No Grade 4 events
a Inklusive pneumocystis jirovecii (carinii) pneumoni (PJP, PCP)
a Includes pneumocystis jirovecii (carinii) pneumonia (PJP, PCP)
a Inklusive tilfælde af nefrotisk syndrom.
a Includes cases of nephrotic syndrome.
a Intent to Treat (ITT) -population
a Intent to Treat (ITT) population
a Intent-to-treat-analyse hvor manglende værdier anses for svigt.
a Intent-to-treat analysis, with missing values considered as failures.
a Intent-to-treat-population under anvendelse af den sidste observation i studiet før glykæmisk nødmedicin.
a Intent-to-treat population using last observation in study prior to glycaemic rescue therapy.
a Intent-To-Treat-population – last observation carried forward. b Justeret middelværdi. c P < 0,05 for behandlingsforskel.
a Intent to treat population – last observation carried forward b Adjusted mean c P<0.05 for treatment difference
a Interferon alfa-2a 9 MIE 3x/ugentlig b Bevacizumab 10 mg/kg hver 2. uge
a Interferon alfa-2a 9 MIU 3x/week b Bevacizumab 10 mg/kg q 2 wk
a IRC-vurderet.
a IRC evaluated;
a ITT-analyse – intention-to-treat population, inkluderer alle lipiddata i studiets forløb uanset overholdelse af studiebehandlingen b ”I behandling” analyse – analyse, der begrænser sig til den periode, hvor patienterne faktisk var i behandling.
a ITT analysis – intent-to-treat population, includes all lipid data throughout the duration of the study irrespective of adherence to the study treatment. b On-treatment analysis – analysis restricted to the time period that patients actually received treatment.
a Jævnfør investigators individuelle anbefalinger ved det foregående besøg, f.eks. afhængigt af om patienten har haft hypoglykæmi.
aAccording to the individualised recommendation by the investigator at the previous visit, for example depending on whether the patient has experienced hypoglycaemia.
a Kalkuleret som anidulafungin minus fluconazol b Med eller uden samtidig candidæmi c Intra-abdominal d Data for patienter med et enkelt patogen ved baseline. e 98.3% konfidensinterval, justeret post-hoc for gentagne sammenligninger ved sekundære tidspunkter.
a Calculated as anidulafungin minus fluconazole bWith or without concurrent candidaemia c Intra-abdominal d Data presented for patients with a single baseline pathogen. e 98.3% confidence intervals, adjusted post hoc for multiple comparisons of secondary time points.
a Kaplan-Meier estimater b Brookmeyer og Crowley metodologi c Stratificeret log-rank test (strata: KRAS-status, tid siden diagnosticering af første metastase, region)
a Kaplan-Meier estimates b Methodology of Brookmeyer and Crowley c Stratified log-rank test (strata: KRAS status, time since diagnosis of first metastasis, region)
a Kaplan-Meier hyppighedsestimater
n=967 22 (2.63%)
a Kaplan-Meier-estimat b Estimatet af Hazard ratio er baseret på Cox' proportionelle risikomodel justeret for stratifikationsfaktorer: 2- mikroglobulin, albumin og region.
a Kaplan-Meier estimate. b Hazard ratio estimate is based on a Cox proportional-hazard model adjusted for stratification factors: β2-microglobulin, albumin, and region.
a Kaplan-Meier-estimat. b Estimatet af hazards ratio er baseret på en Cox proportional hazard-model justeret for stratifikationsfaktorer: β2 ­mikroglobulin, albumin og region.
a Kaplan-Meier estimate. b Hazard ratio estimate is based on a Cox proportional-hazard model adjusted for stratification factors: β2 ­microglobulin, albumin, and region.
A Kontroller at der er nok insulin til din dosis.
Check if you have enough insulin for your dose.
a Kritierne for doseringsgenoptagelse er gældende for alle patienter ved starten af næste cyklus, uanset om kritierne for doseringsafbrydelse blev mødt eller ej.
a Resumption criteria applied to the start of the next cycle for all patients regardless of whether or not the interruption criteria were met.
a Logistisk regressionsmodel justeret for stratificeringsvariable i randomiseringen
a – Logistic regression model adjusted for randomisation stratification variables
a M = måneder b Reduktion i influenzasygdom bekræftet ved dyrkning i forhold til placebo. c Data præsenteret for klinisk studie D153-P504 er for deltagere i studiet, som fik to doser vaccine i studiet.
a M = months b Reduction in culture-confirmed influenza illness relative to placebo. c Data presented for clinical trial D153-P504 are for study participants who received two doses of study vaccine.
a M = måneder bAntal deltagere i undersøgelsen til analysen af virkningen i år 1. c Reduktion i influenzasygdom bekræftet ved dyrkning i forhold til placebo. d Data præsenteret for klinisk studie D153-P504 er for deltagere i studiet, som fik to doser vaccine i studiet.
a M = months b Number of study participants for year 1 efficacy analysis. c Reduction in culture-confirmed influenza illness relative to placebo. d Data presented for clinical trial D153-P504 are for study participants who received two doses of study vaccine.
a M = måneder.
a M = months.
a med ritonavir oral opløsning: 80 mg/ml
a with ritonavir oral solution: 80 mg/ml
a median
9.7